Brief: Icosavax Announces Positive Topline Interim Phase 1/1B Results For VLP Vaccine Candidate IVX-121 Against Rsv

Icosavax

28/06/2022 22:29

June 28 (Reuters) - Icosavax Inc  ICVX.O :
    * ICOSAVAX ANNOUNCES POSITIVE TOPLINE INTERIM PHASE 1/1B
RESULTS
FOR VLP VACCINE CANDIDATE IVX-121 AGAINST RSV
    * ICOSAVAX - IVX-121 SHOWED ROBUST IMMUNOLOGIC RESPONSE TO
RSV,
WITH COMPARABLE GMT LEVELS ACHIEVED AT DAY 28 IN BOTH YOUNG AND
OLDER ADULT GROUPS
    * ICOSAVAX INC - IVX-121 WAS GENERALLY WELL TOLERATED WITH
NO
VACCINE-RELATED SAES
    * ICOSAVAX INC - PLANS TO FILE AN IND SUBMISSION AND
INITIATE A
PHASE 1 TRIAL FOR IVX-A12, A COMBINATION BIVALENT RSV + HMPV VLP
CANDIDATE, IN 2H 2022

Source text for Eikon:  urn:newsml:reuters.com:*:nGNX77YgLc
Further company coverage:  ICVX.O 

 ((Reuters.Briefs@thomsonreuters.com;))